EUVIMEDEUVIMED entdecken
Crossref

Primary cutaneous extranodal natural killer/T cell lymphoma with delayed expression of CD56

Aiko Kobayashi, Hiroyuki Goto, Airi Negishi-Asano, Junko Sowa-Osako, Sayaka Tanaka, Chisato Ohe, Kenichi Kohashi, Daisuke Tsuruta, Chiharu Tateishi

European Journal of Dermatology · 2023

DOI: 10.1684/ejd.2023.4583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Aiko Kobayashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, Lymphoma, Extranodal NK-T-Cell.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BackgroundSarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement.ObjectivesTo evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation.Materials & MethodsThis retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients’ medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis.ResultsAt one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response.ConclusionWe suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousSkin NeoplasmsLymphoma, Extranodal NK-T-CellHumansKiller Cells, NaturalCD56 Antigen

Substanzen

CD56 Antigen

Autor:innen und Institutionen

  • Department of Dermatology and.
  • Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Zitieren

APA

Kobayashi, A., Goto, H., Negishi-Asano, A., Sowa-Osako, J., Tanaka, S., Ohe, C., Kohashi, K., Tsuruta, D., & Tateishi, C. (2023). Primary cutaneous extranodal natural killer/T cell lymphoma with delayed expression of CD56. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4583

Vancouver

Kobayashi A, Goto H, Negishi-Asano A, Sowa-Osako J, Tanaka S, Ohe C, et al. Primary cutaneous extranodal natural killer/T cell lymphoma with delayed expression of CD56. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4583

BibTeX
@article{Kobayashi2023,
  author = {Kobayashi, Aiko and Goto, Hiroyuki and Negishi-Asano, Airi and Sowa-Osako, Junko and Tanaka, Sayaka and Ohe, Chisato and Kohashi, Kenichi and Tsuruta, Daisuke and Tateishi, Chiharu},
  title = {Primary cutaneous extranodal natural killer/T cell lymphoma with delayed expression of CD56},
  journal = {European Journal of Dermatology},
  year = {2023},
  doi = {10.1684/ejd.2023.4583}
}
Kostenlos starten →